Cristina Mirelli, S. Marino, A. Bovio, Sara Pederielli, C. Dall’Agnola, A. Giannì, R. Biagi
{"title":"Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort","authors":"Cristina Mirelli, S. Marino, A. Bovio, Sara Pederielli, C. Dall’Agnola, A. Giannì, R. Biagi","doi":"10.3390/dj10050089","DOIUrl":null,"url":null,"abstract":"A retrospective analysis was performed with the aim of understanding whether the risk factors showed in the literature for medication-related osteonecrosis of the jaws (MRONJ) in cancer patients are also relevant in osteoporotic patients taking antiresorptive drugs (ARDs). Data were retrospectively pooled from health records of patients on ARDs who requested a dental visit between January 2006 and April 2020 in the Dental Unit at Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, University of Milan. A total of 434 patients were included. The following variables were collected: sex, age, smoking habit, type of ARD, duration of treatment, route of administration, therapeutic indication, concurrent systemic therapies and pathologies. Statistical analysis confirmed the relevance of chemotherapy, smoking, and immunosuppressive drugs as risk factors. In addition, a higher frequency of MRONJ in osteoporotic patients was reported in our cohort in association with an immunodeficiency disorder of variable origin. In conclusion, the identification of individual risk-profile before dental treatments is crucial for prevention. Anamnesis should include main risk factors, such as immunosuppression, dental extractions, smoking, trauma, and poor dental health. Nevertheless, our suggestion for dental professionals is to conduct a complete medical history of patients who mention long-term per oral therapies with ARDs for osteoporosis. Osteoporotic, as well as cancer patients, may also benefit from periodic monitoring of the ARDs therapy in order to prevent MRONJ.","PeriodicalId":47284,"journal":{"name":"Open Dentistry Journal","volume":"33 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Dentistry Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/dj10050089","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 3
Abstract
A retrospective analysis was performed with the aim of understanding whether the risk factors showed in the literature for medication-related osteonecrosis of the jaws (MRONJ) in cancer patients are also relevant in osteoporotic patients taking antiresorptive drugs (ARDs). Data were retrospectively pooled from health records of patients on ARDs who requested a dental visit between January 2006 and April 2020 in the Dental Unit at Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, University of Milan. A total of 434 patients were included. The following variables were collected: sex, age, smoking habit, type of ARD, duration of treatment, route of administration, therapeutic indication, concurrent systemic therapies and pathologies. Statistical analysis confirmed the relevance of chemotherapy, smoking, and immunosuppressive drugs as risk factors. In addition, a higher frequency of MRONJ in osteoporotic patients was reported in our cohort in association with an immunodeficiency disorder of variable origin. In conclusion, the identification of individual risk-profile before dental treatments is crucial for prevention. Anamnesis should include main risk factors, such as immunosuppression, dental extractions, smoking, trauma, and poor dental health. Nevertheless, our suggestion for dental professionals is to conduct a complete medical history of patients who mention long-term per oral therapies with ARDs for osteoporosis. Osteoporotic, as well as cancer patients, may also benefit from periodic monitoring of the ARDs therapy in order to prevent MRONJ.
通过回顾性分析,了解文献中癌症患者药物相关性颌骨坏死(MRONJ)的危险因素是否也与服用抗吸收药物(ARDs)的骨质疏松患者相关。回顾性收集了2006年1月至2020年4月期间在米兰大学Ospedale Maggiore Policlinico基金会Granda IRCCS牙科部门要求牙科就诊的ARDs患者的健康记录。共纳入434例患者。收集以下变量:性别、年龄、吸烟习惯、ARD类型、治疗持续时间、给药途径、治疗指征、并发全身治疗和病理。统计分析证实化疗、吸烟和免疫抑制药物是相关的危险因素。此外,在我们的队列中,骨质疏松症患者中MRONJ的发生率较高,与不同来源的免疫缺陷疾病有关。总之,在牙科治疗前确定个人风险状况对预防至关重要。记忆应包括主要危险因素,如免疫抑制、拔牙、吸烟、创伤和牙齿健康状况不佳。然而,我们对牙科专业人员的建议是对骨质疏松症ARDs长期口服治疗的患者进行完整的病史调查。骨质疏松症和癌症患者也可能受益于定期监测ARDs治疗,以防止MRONJ。